TCG
BMY icon

Transcendent Capital Group’s Bristol-Myers Squibb BMY Stock Holding History

Transcendent Capital Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$453K Buy
7,461
+1,564
+27% +$91.2K 0.21% 78
2025
Q4 		$318K Buy
+5,897
New +$284K 0.14% 91
2025
Q1 		– Sell
-4,678
Closed -$265K – 127
2024
Q4 		$265K Buy
4,678
+4,486
+2,336% +$251K 0.14% 86
2024
Q3 		$9.93K Buy
+192
New +$9.01K 0.01% 360

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Transcendent Capital Group's BMY Position: Q1 2026 in Review

Transcendent Capital Group increased its Bristol-Myers Squibb (BMY) stake by 27% in Q1 2026, buying an estimated $91.2K and bringing the position to 7,461 shares worth $453K. The position accounts for 0.21% of the portfolio, ranked #78.

Transcendent Capital Group first reported a position in BMY in Q3 2024 and has held it in 4 quarters since. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Transcendent Capital Group held 7,461 shares of Bristol-Myers Squibb worth $453K as of Q1 2026.
  • Transcendent Capital Group bought 1,564 Bristol-Myers Squibb shares in Q1 2026, an estimated $91.2K.
  • Bristol-Myers Squibb made up 0.21% of Transcendent Capital Group's portfolio in Q1 2026, its #78 holding.
  • Transcendent Capital Group first reported a position in Bristol-Myers Squibb in Q3 2024 and has held it in 4 quarters since.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Transcendent Capital Group's 13F filing for Q1 2026, filed 27 Apr 2026.